Rezultati - David W. Cescon
- Showing 1 - 20 results of 59
- Go to Next Page
-
1
-
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
A risk haplotype in the Solute Carrier Family 22A4/22A5 gene cluster influences phenotypic expression of Crohn’s disease od William G. Newman, Xiangjun Gu, Richard F. Wintle, David W. Cescon, Mehrdad Yazdanpanah, Xiangdong Liu, Vanya Peltekova, Mark Van Oene, Christopher I. Amos, Katherine A. Siminovitch
Izdano 2005Artigo -
12
-
13
Genetic Polymorphisms and Head and Neck Cancer Outcomes: A Review od Jessica Hopkins, David W. Cescon, Darren Tse, Penelope A. Bradbury, Wei Xu, Clement Ma, Paul Wheatley‐Price, John Waldron, David P. Goldstein, François Meyer, Isabelle Bairati, Geoffrey Liu
Izdano 2008Revisão -
14
TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer od Rebecca Dent, David W. Cescon, Thomas Bachelot, Kyung Hae Jung, Zhi‐Ming Shao, Shigehira Saji, Tiffany A. Traina, Petra Vuković, Darlington Mapiye, Micah J. Maxwell, Peter Schmid, Javier Cortés
Izdano 2023Artigo -
15
Functional Characterization of CFI-400945, a Polo-like Kinase 4 Inhibitor, as a Potential Anticancer Agent od Jacqueline M. Mason, Dan Lin, Wei Xin, Yi Che, Yi Yao, Reza Kiarash, David W. Cescon, Graham C. Fletcher, Donald E. Awrey, Mark R. Bray, Guohua Pan, Tak W. Mak
Izdano 2014Artigo -
16
Disruption of the anaphase-promoting complex confers resistance to TTK inhibitors in triple-negative breast cancer od Kelsie L. Thu, Jennifer Silvester, Mitchell J. Elliott, Wail Ba-Alawi, Meghan Duncan, Andrea C. Elia, Arvind Singh Mer, Petr Smirnov, Zhaleh Safikhani, Benjamin Haibe‐Kains, Tak W. Mak, David W. Cescon
Izdano 2018Artigo -
17
Topoisomerase 1 Inhibition in MYC-Driven Cancer Promotes Aberrant R-Loop Accumulation to Induce Synthetic Lethality od Peter Lin, Corey Lourenco, Jennifer Cruickshank, Luís Palomero, Jenna E. van Leeuwen, Amy H.Y. Tong, Katherine Chan, Samah El Ghamrasni, Miguel Ángel Pujana, David W. Cescon, Jason Moffat, Linda Z. Penn
Izdano 2023Artigo -
18
TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperabl... od Peter Schmid, Mafalda Oliveira, Joyce O’Shaughnessy, Massimo Cristofanilli, Stephanie L. Graff, Seock-Ah Im, Sherene Loi, Shigehira Saji, Shusen Wang, David W. Cescon, Tina Hovey, Agata Nawrot, KY Tse, Petra Vuković, Giuseppe Curigliano
Izdano 2025Artigo -
19
Functional variants of OCTN cation transporter genes are associated with Crohn disease od Vanya Peltekova, Richard F. Wintle, Laurence A. Rubin, Christopher I. Amos, Qiqing Huang, Xiangjun Gu, William G. Newman, Mark Van Oene, David W. Cescon, Gordon R. Greenberg, Anne M. Griffiths, Peter St George‐Hyslop, Katherine A. Siminovitch
Izdano 2004Artigo -
20
Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086 od Sherene Loi, Sylvia Adams, Peter Schmid, Javier Cortés, David W. Cescon, Eric P. Winer, Deborah Toppmeyer, Hope S. Rugo, Michelino De Laurentiis, Rita Nanda, Hiroji Iwata, Ahmad Awada, Antoinette R. Tan, A. Wang, Gursel Aktan, Vassiliki Karantza, Roberto Salgado
Izdano 2017Artigo
Iskalna orodja:
Sorodne teme
Cancer
Biology
Medicine
Internal medicine
Cancer research
Genetics
Breast cancer
Oncology
Gene
Immunotherapy
Cell biology
Pembrolizumab
Biochemistry
Immunology
Triple-negative breast cancer
Chemotherapy
Clinical trial
DNA
DNA repair
Gene expression
Immune system
Metastatic breast cancer
Biomarker
Carcinogenesis
Cell cycle
Chemistry
Epigenetics
Pathology
Pharmacology
Adverse effect